Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UltraSlice is a gene-editing protein technology platform developed by Factor Bioscience. It utilizes mRNA-based delivery to express gene-editing proteins for efficient and precise transgene insertion into the genome, specifically targeting sites like the TRAC locus in primary human T cells and induced pluripotent stem cells (iPSCs). The platform is designed to support the development of next-generation cell therapies, including allogeneic CAR-T cells, for applications in oncology, autoimmune diseases, and rare diseases. To enhance performance, the technology incorporates modified nucleotides, such as 5-methoxyuridine, which reduce immunogenicity and improve editing efficiency while maintaining high cell viability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UltraSlice.